DiaMedica Therapeutics Inc. (DMAC): EV/EBITDA Multiple

Public company logo of DiaMedica Pharma (DMAC)

DiaMedica Therapeutics (DMAC) relies on a narrow range of nephrological developments, creating a sharp dependency on clinical trial outcomes. This price chart with the 0.00 metric illustrates the dynamics of a company whose R&D expenditures and strict FDA oversight limit entry into the sector. In the future, molecule synthesis via contractors will ensure high margins once patents for kidney medications are secured.

DiaMedica Pharma - DMAC Enterprise Value to Operating Income Before Depreciation (period 11/23/2025 - 11/15/2026)

DMAC (DiaMedica Pharma): analytical breakdowns and indicator data

- market price and analyst price targets:
Price Chart DiaMedica Corp|DMAC - Analyst Consensus Forecast
- stock exchange capitalization data:
Market Capitalization DiaMedica Pharma|DMAC - Company Buyout Price
- issuer book value statistics:
Book Value per Share DiaMedica Therapeutics|DMAC - Accounting Capitalization|Market Value to Book Value Ratio diamedica.com|DMAC - Total Business Assets
- company liabilities and liquidity data:
Total Debt to Capital DiaMedica Therapeutics|DMAC - Long-Term Liabilities to Capital|Short-Term Debt to Equity Ratio diamedica.com|DMAC - Company Cumulative Debt|Debts to Book Capitalization DiaMedica Pharma|DMAC - Company Long-Term Indebtedness|Company Short-Term Debts DiaMedica Therapeutics|Quick Ratio diamedica.com
- financial results and valuation multiples details:
DMAC - Net Profit|Expected Profit DiaMedica Therapeutics|DMAC - Price to Earnings Ratio|Forward P/E Multiple DiaMedica Corp|DMAC - Price to Earnings Adjusted for Growth Rate|EV/EBITDA Multiple DiaMedica Pharma|DMAC - Operating profit before amortization|Net earnings per share (EPS TTM) DiaMedica Therapeutics|DMAC - Net earnings per share for the last four quarters|Quarterly EPS earnings growth diamedica.com|DMAC - Net earnings per share growth this year|Earnings growth forecast for next year DiaMedica Therapeutics
- sales and revenue indicators:
DMAC - Revenue and Sales Volume|Company Future Sales Volume DiaMedica Therapeutics|DMAC - Market Capitalization-to-Revenue Ratio|Forward Price-to-Revenue Multiple DiaMedica Corp|DMAC - Revenue Change YoY (Last 12 Months)
Initial company analysis:DiaMedica Therapeutics Inc. DMAC
Product sample of DiaMedica Therapeutics Inc

Fundamental asset screening requires a precise determination of business value relative to its operational efficiency. The EV/EBITDA multiple on this chart compares the total market value of the company, including debt, against its earnings before interest, taxes, depreciation, and amortization. The stability of this line often indicates growth stagnation, despite the high maturity of the structure. For DiaMedica Therapeutics (DMAC), this metric is supported by the neutral geopolitical status of the biomedical sector.

Competitor analysis for DiaMedica Therapeutics

Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Travere Corp TVTX|EV/EBITDA Multiple Ardelyx, Inc. ARDX|ProKidney Corp - EV/EBITDA Multiple|Total Company Value to Operating Income Before Depreciation Ratio Akebia Therapeutics, Inc. AKBA|TVRD: EV/EBITDA Multiple|Enterprise Value to Operating Income Before Depreciation UNCY|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Rockwell Medical, Inc.|Enterprise Value to Operating Income Before Depreciation CVKD (Cadrenal Therapeutics)|Enterprise Value to EBITDA Ratio CDT (Conduit Therapeutics)|CALT - Company Value to EBITDA|Renalytix - Enterprise Value to EBITDA Ratio|zyversa.com (ZVSA) - Company Value to EBITDA